highperformr logo

Par Pharmaceutical's Overview

Total employees1409
HeadquartersMalvern
Founded1978

Par Pharmaceutical, a prominent operating company of Endo International plc, is engaged in the development, manufacturing, and marketing of a broad portfolio of high-quality generic and specialty branded pharmaceuticals. Originally founded in 1978, Par established a strong reputation for producing affordable medicines, particularly in difficult-to-manufacture product categories. In 2015, Par Pharmaceutical was acquired by Endo International, a move that significantly expanded Endo's generics segment and capabilities, especially in controlled substances, injectables, and modified-release oral solids. Today, the Par brand continues to represent a significant portion of Endo's generic offerings, focusing on providing value to the healthcare system by increasing access to essential medications.

Where is Par Pharmaceutical's Headquarters?

HQ Function

Serves as the main U.S. operational hub for Endo International, overseeing strategic, commercial, R&D coordination, and administrative functions for its various businesses, including the Par Pharmaceutical product lines.

Notable Features:

The Malvern campus is a modern corporate facility designed to support a collaborative work environment for pharmaceutical innovation and operations. It houses key decision-makers and functional teams for Endo's U.S. business.

Work Culture:

The work culture, reflecting Endo's broader corporate values, emphasizes quality, integrity, and a patient-centric approach. There's a focus on innovation in pharmaceutical development and operational excellence within a highly regulated industry.

HQ Significance:

This location is central to Endo's operations in the United States, its largest market. It plays a critical role in managing the development, manufacturing oversight, and commercialization of products under the Par Pharmaceutical brand and other Endo segments.

Values Reflected in HQ: The headquarters likely reflects Endo's commitment to scientific advancement, operational efficiency, employee well-being, and maintaining high standards of quality and compliance in the pharmaceutical sector.

Location:

Through its parent company Endo International, Par Pharmaceutical's products and operations are part of a global network. Endo has a primary commercial focus in the U.S. market, supported by manufacturing facilities in the U.S. and India, and R&D centers in both countries. Global functions include research and development, API sourcing, finished product manufacturing, quality control and assurance, regulatory affairs, and supply chain management, ensuring the availability of its pharmaceuticals worldwide where approved.

Street Address:

1400 Atwater Dr

City:

Malvern

State/Province:

Pennsylvania

Country:

USA

Par Pharmaceutical's Global Presence

Chestnut Ridge, New York/USA

Address: One Ram Ridge Road, Chestnut Ridge, NY 10977, USA

Major site for manufacturing and distributing generic pharmaceuticals for the U.S. market, with specialized capabilities.

Irvine, California/USA

Address: 19270 Mccollough, Irvine, CA 92612, USA (Example, verify exact Endo sterile facility address)

Provides specialized manufacturing capabilities for sterile injectable drugs, serving hospitals and clinics primarily in North America.

Chennai, Tamil Nadu/India

Address: Plot No. SP-DSG, 17, 18, 19 & 20, Pharma SEZ, TICEL Bio Park Taramani, Chennai, Tamil Nadu 600113, India (Address for Par Formulations Pvt. Ltd.)

Supports Endo's global generics supply chain with R&D and manufacturing capabilities, leveraging regional expertise and cost-effectiveness for both local and international markets.

Dublin, Ireland

Address: First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland

Global corporate functions and strategic oversight of all Endo operations, including those related to Par Pharmaceutical.

Buying Intent Signals for Par Pharmaceutical

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Par Pharmaceutical

As of April 2025, Par Pharmaceutical' leadership includes:

Blaise Coleman - President and Chief Executive Officer
Mark T. Bradley - Executive Vice President and Chief Financial Officer
Patrick Barry - President, Global Commercial Operations
Matthew J. Maletta - Executive Vice President, Chief Legal Officer, and Company Secretary
Scott E. Smith - Executive Vice President and Chief Human Resources Officer

Investors of Par Pharmaceutical

Par Pharmaceutical has been backed by several prominent investors over the years, including:

Par Pharmaceutical was acquired by Endo International plc in 2015.
Endo International completed a financial restructuring and emerged from Chapter 11 in April 2023.
Post-restructuring, Endo International is a private company primarily owned by a consortium of its former lenders and noteholders.

Executive New Hires/Exits in the Last 12 Months

Hire7
Exits5

Endo International underwent significant leadership and board changes as part of its financial restructuring process, which concluded with its emergence from Chapter 11 in April 2023. This involved the appointment of a new Board of Directors and affirmation of key executive leadership to guide the newly restructured private company.

Departures

Paul Campanelli, Paul Campanelli, along with other pre-restructuring board members, stepped down upon the company's emergence from Chapter 11 and the formation of a new board.
Nancy J. Hutson, Ph.D., Departed from the Board of Directors as part of the restructuring and emergence process.
Michael Hyatt, Departed from the Board of Directors as part of the restructuring and emergence process.
William P. Montague, Departed from the Board of Directors as part of the restructuring and emergence process.
Todd B. Sisitsky, Departed from the Board of Directors as part of the restructuring and emergence process.

New Appointments:

Mark G. Barberio, Appointed Chairman of the new Board of Directors upon Endo's emergence from Chapter 11.
James R. Benner, Appointed to the new Board of Directors.
Blaise Coleman, Continued as President & CEO and appointed to the new Board of Directors.
Patrick J. Lonergan, Appointed to the new Board of Directors.
Charles A. Rowland, Jr., Appointed to the new Board of Directors.
Justin C. Smith, Appointed to the new Board of Directors.
Geoffrey M. Glass, Appointed to the new Board of Directors.

Technology (Tech Stack) used by Par Pharmaceutical

Discover the tools Par Pharmaceutical uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Par Pharmaceutical Email Formats and Examples

Endo International, the parent company of Par Pharmaceutical, likely utilizes standard corporate email formats. The most common patterns are variations of [first name], [last name], and initials.

first.last@endo.com (e.g., john.doe@endo.com) OR flast@endo.com (e.g. jdoe@endo.com)

Format

john.doe@endo.com

Example

80%

Success rate

News and media

Endo InternationalApril 26, 2023

Endo International Successfully Completes Financial Restructuring and Emerges from Chapter 11 Proceedings

Endo International plc announced that it has successfully completed its financial restructuring and emerged from Chapter 11 proceedings. The Company moves forward with a significantly stronger financial foundation, reduced debt, and a new, private ownership structure. Blaise Coleman will continue to lead Endo as President and CEO, and a new Board of Directors has been appointed....more

Endo InternationalNovember 16, 2023

Endo Announces FDA Approval and Launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection

Endo International plc announced that its Par Pharmaceutical, Inc. operating company has begun shipping dexmedetomidine hydrochloride in 0.9% sodium chloride injection, a ready-to-use formulation in a 100mL flexible container. This product is the generic equivalent of Precedex®....more

Endo InternationalFebruary 29, 2024

Endo Announces FDA Approval and Launch of Vasopressin Injection, USP

Endo International plc announced that its Par Sterile Products business has begun shipping Vasopressin Injection, USP, 20 Units/mL, multidose vial, an authorized generic version of Par Pharmaceutical's Vasostrict®....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Par Pharmaceutical, are just a search away.